CN Patent

CN106794157A — 包含rpl554的液体吸入制剂

Assigned to Verona Pharma Ltd · Expires 2017-05-31 · 9y expired

What this patent protects

本发明涉及一种适合于通过吸入施用的液体药物组合物，其包含稀释剂和9,10‑二甲氧基‑2‑(2,4,6‑三甲基苯基亚氨基)‑3‑(N‑氨基甲酰基‑2‑氨基乙基)‑3,4,6,7‑四氢‑2H‑嘧啶并[6,1‑a]异喹啉‑4‑酮(RPL554)或其药学上可接受的盐的颗粒的悬浮液。还描述了本发明的液体药物组合物用于治疗人体或动物体。

USPTO Abstract

本发明涉及一种适合于通过吸入施用的液体药物组合物，其包含稀释剂和9,10‑二甲氧基‑2‑(2,4,6‑三甲基苯基亚氨基)‑3‑(N‑氨基甲酰基‑2‑氨基乙基)‑3,4,6,7‑四氢‑2H‑嘧啶并[6,1‑a]异喹啉‑4‑酮(RPL554)或其药学上可接受的盐的颗粒的悬浮液。还描述了本发明的液体药物组合物用于治疗人体或动物体。

Drugs covered by this patent

Patent Metadata

Patent number
CN106794157A
Jurisdiction
CN
Classification
—
Expires
2017-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Verona Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.